Rigel Pharmaceuticals | RIGL - Passività Correnti





Passività Correnti Cambiamento Data
Agenus USD 323.49M 36.36M 2025-12
Amgen USD 25.49B 3.7B 2025-12
Anika Therapeutics USD 21.91M 2.82M 2025-12
Arrowhead Research USD 347.42M 151.94M 2025-12
AstraZeneca USD 30.62B 3.44B 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Bristol-Myers Squibb USD 28.14B 608M 2025-09
Celldex Therapeutics USD 50.99M 4.53M 2025-12
Daiichi Sankyo JPY 778.55B 77.51B 2025-12
Eli Lilly USD 35.23B 4.91B 2025-12
Halozyme Therapeutics USD 177.09M 660.14M 2025-12
Heron Therapeutics USD 96.1M 6.39M 2025-12
Intrexon USD 23.02M 38K 2024-06
Ionis Pharmaceuticals USD 783M 120.46M 2025-12
Karyopharm Therapeutics USD 87.16M 12.06M 2025-09
Ligand Pharmaceuticals USD 37.45M 6.91M 2025-12
MacroGenics USD 43.11M 1.36M 2025-12
Neurocrine Biosciences USD 743.4M 105.4M 2025-12
Pfizer USD 36.6B 1.13B 2025-09
Regeneron Pharmaceuticals USD 4.37B 56.7M 2025-12
Rigel Pharmaceuticals USD 94.4M 7.76M 2025-09
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Ultragenyx Pharmaceutical USD 340.02M 46.78M 2025-09
Veracyte USD 59.94M 12.22M 2025-12